To use this feature, join Babbler easily !
Babbler allows PR people and reporters to collaborate a better way.
By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.
Their newsrooms are already on Babbler
You're 1 click away from signing up
Nice to see you again !
Sanofi remporte un procès sur une communication médiatique trompeuse
minutes reading time
minute reading time
HØRSHOLM, DENMARK - March 5, 2018 - Sanofi has won a legal challenge against Novo Nordisk in the Danish Maritime and Commercial High Court. The ruling relates to information issued to the media on September 15, 2017, by Novo Nordisk around its DEVOTE 3 study.
The court upheld Sanofi’s assertion that Novo Nordisk’s description of the study in the announcement was “misleading in its form and structure and must be deemed to constitute advertising of Tresiba® ”. As such, the court found that Novo Nordisk had acted in violation of good marketing practice of the Danish Marketing Practices Act and in violation of the Danish Pharmaceuticals Act. “We are pleased with the Danish Maritime and Commercial High Court's decision to prohibit further use of this document by Novo Nordisk,” said Rasmus Schädler Villemoes, General Manager of Sanofi's diabetes division in Denmark, adding: "That said, the decision of the Maritime and Commercial Court is just the latest of a number of recent cases that have been dealt with by both ENLI (Ethical Committee for the Pharmaceutical Industry) and the Danish Medicines Agency, in which Novo Nordisk's advertising for Tresiba has in each case been found to be misleading. From our side, Novo Nordisk appears to have continued to systematically mislead with their advertising for Tresiba, despite the negative results of the legal cases. "
Novo Nordisk was prohibited from further publishing this information or sending it to the healthcare professionals or the public.
Novo Nordisk has declared that they are not currently using the press release in this way and will not use it in future. Novo Nordisk was also ordered to pay Sanofi’s legal costs relating to the action. Just this morning Sanofi has again received information that yet another complaint case against Novo Nordisk has been won at the pharmaceutical industry's self-regulatory body ENLI. This case also regards Novo Nordisk's advertising material for Tresiba, which was found to be in violation of the rules on pharmaceutical advertising. Novo Nordisk is ordered to stop using the material and is fined DKK 40,000 + VAT “Novo Nordisk loses these cases in ENLI, the Danish Medicines Agency and now also the courts. We can only hope that Novo Nordisk will stop using misleading advertising for Tresiba," says Rasmus Schädler Villemoes. Sanofi will continue to follow closely any further publicity around the misleading information conveyed in the DEVOTE 3 press release. About Sanofi Sanofi is dedicated to supporting people through their
Congratulations, you're registered on Babbler!
Discover now all the news waiting for you on Babbler: visit your newsfeed.!
Your topics have been selected, you can change it by clicking here